EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors
Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.
Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
CHMP Grants Positive Opinion to Tislelizumab/Chemo in Front-Line ES-SCLC
Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.
AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC
An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.
Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.
Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma
Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.
Solnerstotug Shows Promising Preliminary Data in PD-L1 Resistant Tumors
No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.
Theranostics and Radiopharmaceutical Use May Enhance Cancer Care
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis
Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.
PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases
Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.
Local Excision After Chemo Achieves Negative Margins in Rectal Cancer
A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.
CHMP Recommends Acalabrutinib Combo Approval in Untreated MCL
Results from the phase 3 ECHO trial showed PFS and OS improvements with acalabrutinib in the first-line treatment of MCL compared with standard of care.
Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer
Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Exploring Novel Treatment Developments in Radiation Oncology
Adaptive radiation may help individualize therapy based on transient factors patients are faced with while receiving treatment for cancer.
Optimizing Opportunities to Deliver Personalized Radiation Oncology Care
Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.
Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC
The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.
Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment
Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.
Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies
“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.
Multidisciplinary Care is ‘Incredibly Important’ for Managing GI Cancers
“[There] is a need to make sure that everybody is coming in and bringing their expertise together,” Valerie Lee, MD, said.
FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer
Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.
ASTCT Women’s History Month Spotlight: Terri Lynn Shigle, PharmD
For Terri Lynn Shigle, PharmD, the field of hematology-oncology is deeply personal. Having lost loved ones to cancer, she was drawn to a career where she could make a meaningful difference in patient care.
ASTCT Women’s History Month Spotlight: Sung-Yun Pai, MD
In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy.
Prioritizing Climate Hazard Preparedness Following NSCLC Surgery
Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.
Omitting Breast Surgery Stalls Cancer Recurrence in Exceptional Responders
At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.
FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC
Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.
Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer
Tisotumab vedotin elicited a median OS of 11.5 months vs 9.5 months with chemotherapy in advanced cervical cancer in the phase 3 innovaTV 301 trial.
Sharing Knowledge is Key for Climate Disaster Preparedness in Cancer Care
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
